1.78 USD
-0.05 (-2.73%)
1.78 USD
0 (0%)
Overall PLX gets a fundamental rating of 5 out of 10. We evaluated PLX against 533 industry peers in the Biotechnology industry. PLX has an average financial health and profitability rating. PLX has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
PLX had positive earnings in the past year.
PLX had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: PLX reported negative net income in multiple years.
PLX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
PLX has a Return On Assets of 8.00%. This is amongst the best in the industry. PLX outperforms 93.25% of its industry peers.
PLX has a Return On Equity of 12.57%. This is amongst the best in the industry. PLX outperforms 94.00% of its industry peers.
PLX's Return On Invested Capital of 12.68% is amongst the best of the industry. PLX outperforms 95.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8% | ||
| ROE | 12.57% | ||
| ROIC | 12.68% |
ROA(3y)-4.31%
ROA(5y)-11.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PLX's Profit Margin of 10.13% is amongst the best of the industry. PLX outperforms 91.93% of its industry peers.
PLX has a Operating Margin of 13.28%. This is amongst the best in the industry. PLX outperforms 92.87% of its industry peers.
Looking at the Gross Margin, with a value of 57.53%, PLX is in the better half of the industry, outperforming 77.30% of the companies in the same industry.
In the last couple of years the Gross Margin of PLX has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.28% | ||
| PM (TTM) | 10.13% | ||
| GM | 57.53% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-7.42%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), PLX is creating some value.
The number of shares outstanding for PLX has been increased compared to 1 year ago.
The number of shares outstanding for PLX has been increased compared to 5 years ago.
PLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -1.98, we must say that PLX is in the distress zone and has some risk of bankruptcy.
PLX's Altman-Z score of -1.98 is in line compared to the rest of the industry. PLX outperforms 52.16% of its industry peers.
PLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.98 |
ROIC/WACC1.4
WACC9.03%
2.3 Liquidity
PLX has a Current Ratio of 2.72. This indicates that PLX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.72, PLX is doing worse than 66.98% of the companies in the same industry.
PLX has a Quick Ratio of 1.84. This is a normal value and indicates that PLX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.84, PLX is doing worse than 76.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 1.84 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 153.85% over the past year.
Looking at the last year, PLX shows a very negative growth in Revenue. The Revenue has decreased by -18.47% in the last year.
PLX shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.48% yearly.
EPS 1Y (TTM)153.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-18.47%
Revenue growth 3Y11.67%
Revenue growth 5Y-0.48%
Sales Q2Q%-0.6%
3.2 Future
PLX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 238.30% yearly.
Based on estimates for the next years, PLX will show a very strong growth in Revenue. The Revenue will grow by 44.15% on average per year.
EPS Next Y337.67%
EPS Next 2Y328.35%
EPS Next 3Y238.3%
EPS Next 5YN/A
Revenue Next Year12.26%
Revenue Next 2Y40.47%
Revenue Next 3Y44.15%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
PLX is valuated quite expensively with a Price/Earnings ratio of 25.43.
Based on the Price/Earnings ratio, PLX is valued cheaply inside the industry as 92.87% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 26.31. PLX is around the same levels.
PLX is valuated cheaply with a Price/Forward Earnings ratio of 3.23.
Based on the Price/Forward Earnings ratio, PLX is valued cheaply inside the industry as 99.44% of the companies are valued more expensively.
PLX is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.59, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.43 | ||
| Fwd PE | 3.23 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PLX indicates a rather cheap valuation: PLX is cheaper than 97.19% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 10.11 |
4.3 Compensation for Growth
PLX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PLX's earnings are expected to grow with 238.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.08
PEG (5Y)N/A
EPS Next 2Y328.35%
EPS Next 3Y238.3%
5. Dividend
5.1 Amount
No dividends for PLX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.78
-0.05 (-2.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners15.15%
Inst Owner Change16.94%
Ins Owners3.5%
Ins Owner Change0%
Market Cap143.15M
Revenue(TTM)53.40M
Net Income(TTM)6.28M
Analysts80
Price Target14.28 (702.25%)
Short Float %5.81%
Short Ratio4.83
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-182.51%
Min EPS beat(2)-265.02%
Max EPS beat(2)-100%
EPS beat(4)1
Avg EPS beat(4)-90.87%
Min EPS beat(4)-265.02%
Max EPS beat(4)27.3%
EPS beat(8)2
Avg EPS beat(8)-112.08%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-19.6%
Min Revenue beat(2)-53.64%
Max Revenue beat(2)14.45%
Revenue beat(4)2
Avg Revenue beat(4)-8.41%
Min Revenue beat(4)-53.64%
Max Revenue beat(4)14.45%
Revenue beat(8)5
Avg Revenue beat(8)3.31%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-21.43%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.43%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.43 | ||
| Fwd PE | 3.23 | ||
| P/S | 2.29 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.84 | ||
| P/tB | 2.84 | ||
| EV/EBITDA | 10.11 |
EPS(TTM)0.07
EY3.93%
EPS(NY)0.55
Fwd EY30.92%
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.78
BVpS0.63
TBVpS0.63
PEG (NY)0.08
PEG (5Y)N/A
Graham Number0.99
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8% | ||
| ROE | 12.57% | ||
| ROCE | 15.12% | ||
| ROIC | 12.68% | ||
| ROICexc | 32.84% | ||
| ROICexgc | 32.84% | ||
| OM | 13.28% | ||
| PM (TTM) | 10.13% | ||
| GM | 57.53% | ||
| FCFM | N/A |
ROA(3y)-4.31%
ROA(5y)-11.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-7.42%
F-Score6
Asset Turnover0.79
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 91.23% | ||
| Cap/Sales | 2.02% | ||
| Interest Coverage | 10.74 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 1.84 | ||
| Altman-Z | -1.98 |
F-Score6
WACC9.03%
ROIC/WACC1.4
Cap/Depr(3y)84.19%
Cap/Depr(5y)86.74%
Cap/Sales(3y)1.83%
Cap/Sales(5y)2.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)153.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y337.67%
EPS Next 2Y328.35%
EPS Next 3Y238.3%
EPS Next 5YN/A
Revenue 1Y (TTM)-18.47%
Revenue growth 3Y11.67%
Revenue growth 5Y-0.48%
Sales Q2Q%-0.6%
Revenue Next Year12.26%
Revenue Next 2Y40.47%
Revenue Next 3Y44.15%
Revenue Next 5YN/A
EBIT growth 1Y155.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y67.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.67%
OCF growth 3YN/A
OCF growth 5YN/A
PROTALIX BIOTHERAPEUTICS INC / PLX FAQ
What is the ChartMill fundamental rating of PROTALIX BIOTHERAPEUTICS INC (PLX) stock?
ChartMill assigns a fundamental rating of 5 / 10 to PLX.
What is the valuation status of PROTALIX BIOTHERAPEUTICS INC (PLX) stock?
ChartMill assigns a valuation rating of 6 / 10 to PROTALIX BIOTHERAPEUTICS INC (PLX). This can be considered as Fairly Valued.
What is the profitability of PLX stock?
PROTALIX BIOTHERAPEUTICS INC (PLX) has a profitability rating of 5 / 10.
Can you provide the PE and PB ratios for PLX stock?
The Price/Earnings (PE) ratio for PROTALIX BIOTHERAPEUTICS INC (PLX) is 25.43 and the Price/Book (PB) ratio is 2.84.
Can you provide the expected EPS growth for PLX stock?
The Earnings per Share (EPS) of PROTALIX BIOTHERAPEUTICS INC (PLX) is expected to grow by 337.67% in the next year.